canyon landscape

THC-306 (foresiGHt)

A multicenter, randomized, parallel-arm, placebo-controlled (double-blind) and active controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily somatropin product in adults with growth hormone deficiency.


Primary objective is to evaluate the efficacy of once-weekly lonapegsomatropin compared to placebo at 38 weeks in adults with Growth Hormone Deficiency (GHD). Subject population will consist of Adults with GHD (male and female), either treatment-naïve or not having received GH therapy for at least 12 months prior to screening will be enrolled.

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
Ascendis Pharma Endocrinology
Contact Us

Enrollment Information

Contact Nohemi Ramirez-Castillo at (602) 406-3231